Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of sPLA2 in atherosclerotic plaque from coronary artery disease patient
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of sPLA2 in human HepG2 cells
Inhibition of sPLA2 in human plasma at 25 uM using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of sPLA2 in human plasma using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay
Assay data:9 Active, 4 Activity ≤ 1 nM, 9 Activity ≤ 1 µM, 11 Tested
Ratio of XI50 for inhibition of human recombinant sPLA2 using PAPG to XI50 for inhibition of human recombinant sPLA2 using PAPC
Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in free FA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human recombinant sPLA2 using PAPS as substrate assessed as reduction in 16:0 LPS formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPG as substrate assessed as reduction in 16:0 LPG formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPE as substrate assessed as reduction in 16:0 LPE formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPC as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in 16:0 LPA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 assessed as reduction in free FA formation after 30 mins by HPLC-MS analysis
Inhibition of human recombinant sPLA2 assessed as reduction in 16:0 LPC formation after 30 mins by HPLC-MS analysis
Inhibition of human sPLA2 at 10 uM relative to control
Inhibition of human sPLA2
Identification of proteins required for the processing of the EWS-FLI1 nascent transcript
Assay data:59220 Tested
Summary
InfectX: Pathogen infection siRNA screens
Assay data:115372 Tested
SummaryPubMed Citation
A whole genome RNAi screen highlights components of the ER/Golgi as a prominent source of resistance to immunotoxin-mediated cytotoxicity
Assay data:555 Active, 64752 Tested
Druggable Genome siRNA Screen for Enhancers of Camptothecin in MDA-MB-231 Breast Cancer Cells
Assay data:167 Active, 26449 Tested
Genome-wide high-content siRNA screens for regulators of Parkin translocation in selective mitophagy (Ambion Library)
Assay data:9227 Active, 64752 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on